IQVIA Holdings, Inc.
IQV · Healthcare
$258.35
Cargando gráfico…
Noticias
Últimos titulares de esta acción
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
Veeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.
Medera Presents Late-Breaking Clinical Trial Data at ESC Congress 2026 Demonstrating Durable Improvement in HFpEF Cardiac Filling Pressures Following SRD-002 Gene Therapy
Medera Inc. announced 12-month data from its MUSIC-HFpEF Phase 1/2a clinical trial showing that 80% of patients met the prespecified threshold for normalization of cardiac filling pressures, with approximately 30% reduction in peak exercise pulmonary capillary wedge pressure. The trial demonstrated a favorable safety profile with no treatment-related serious adverse events across all 10 treated patients. Results support advancement to a randomized Phase 2b trial for SRD-002, a single-dose intracoronary AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction.